

To all concerned

February 1, 2017
 Company:FINDEX Inc.
 Representative:President & CEO
 Teruo Aibara
 (Securities code:3649)
 Contact:Director and Head of Administration
 Atsushi Fujita
 (TEL:+81-89-947-3388)

Notice on Establishment of Consolidated Subsidiary

FINDEX Inc. (the "Company") hereby announces that its Board of Directors has resolved at the meeting held today that the Company will establish a new consolidated subsidiary as follows:

1. Purpose of establishment

The Company has resolved to establish a subsidiary by investing a 53.8% stake as follows in order to further expand and enhance its business.

The subsidiary will be established jointly with Eagle Matrix Co., Ltd. ("Eagle Matrix"), which has strengths in business strategy and consulting operations in the data science field, and will be a consulting company specializing in medical strategy, medical data analysis utilizing AI technology and operations related to data health.

Eagle Matrix has a variety of overseas experiences such as engaging in the establishment of new health care service utilizing medical ICT in collaboration with universities, medical institutions and enterprises in Manchester in Britain. Eagle Matrix also widely contributes in relevant fields in Japan by analyzing medical data in collaboration with local governments or by visualizing the health trend of residents in communities and analyzing causal relationships utilizing various statistical methods and thereby developing effective medical and welfare policies or interventions.

Eagle Matrix's staff who participate in the subsidiary have an abundance of experience and networks with overseas government agencies and academic institutions, and are skilled at strategy design for the management, etc. of enterprises and public organizations inside and outside Japan, medical ICT system design and project management.

The subsidiary's business can construct a strong reciprocal relationship with the Company's medical system consultants, large-scale medical institution networks and medical treatment data management solutions, etc. and will exert the maximum synergy on both companies, contributing to the expansion of each party's business.

2. Overview of the consolidated subsidiary to be established

(1)	N a m e	Eagle Matrix Consulting Co., Ltd.	
(2)	L o c a t i o n	Hamamatsu-cho, Minato-ku, Tokyo	
(3)	T i t l e a n d n a m e o f r e p r e s e n t a t i v e	President & CEO: Yoshito Date	
(4)	D e t a i l s o f b u s i n e s s	Medical consulting, medical system consulting	
(5)	C a p i t a l	5 million yen	
(6)	D a t e o f f o u n d a t i o n	February 14, 2017	
(7)	N e t a s s e t s	9 million yen	
(8)	G r o s s a s s e t s	9 million yen	
(9)	Major shareholders and their share-holding ratio	The Company 53.8% Eagle Matrix Co., Ltd. 43.6% Officers and employees of Eagle Matrix Consulting Co., Ltd. 2.6%	
(10)	Relationship between a listed company and the relevant company	C a p i t a l r e l a t i o n s h i p	The Company invests a 53.8% stake in the subsidiary.
		P e r s o n n e l r e l a t i o n s h i p	The Company's representative director will concurrently serve as an outside director.
		T r a n s a c t i o n r e l a t i o n s h i p	Not applicable
		W h e t h e r o r n o t t h e r e l e v a n t c o m p a n y i s a r e l a t e d p a r t y	The relevant company is a consolidated subsidiary of the Company and therefore is a related party.

(11) Other	The Company has resolved at the Board of Directors' meeting held today that the Company will provide the subsidiary with funds up to a total of 100 million yen as needed by subscribing for bonds.
------------	---

3. Overview of the joint investor

(1) Name	Eagle Matrix Co., Ltd.	
(2) Location	Chiyoda-ku, Tokyo	
(3) Title and name of representative	President & CEO: Yoshito Date	
(4) Details of business	Consulting, system consulting	
(5) Capital	25 million yen	
(6) Date of foundation	July 14, 2000	
(7) Net assets	Description is omitted because the information is not disclosed.	
(8) Gross assets	Description is omitted because the information is not disclosed.	
(9) Major shareholders and their share-holding ratio	Description is omitted because the information is not disclosed.	
(10) Relationship between a listed company and the relevant company	Capital relationship	Not applicable
	Personnel relationship	Not applicable
	Transaction relationship	Not applicable
	Whether or not the relevant company is a related party	Not applicable

4. Schedule

(1) Date of resolution of the Board of Directors	February 1, 2017
(2) Scheduled date of foundation	February 14, 2017
(3) Scheduled date of the commencement of business	February 14, 2017

5. Future outlook

The impact on business performance is currently being examined. Notifications of any matters that should be disclosed will be promptly issued.